End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
14.48 USD | -0.14% | +6.08% | +26.13% |
04-30 | Alvotech to Manufacture Humira Biosimilar for Quallent Pharmaceuticals | MT |
04-30 | Alvotech to Make Humira Biosimilar Adalimumab-ryvk for Quallent | MT |
Sales 2024 * | 356M 485M | Sales 2025 * | 606M 826M | Capitalization | 4.06B 5.52B |
---|---|---|---|---|---|
Net income 2024 * | -149M -203M | Net income 2025 * | 30M 40.86M | EV / Sales 2024 * | 15.5 x |
Net Debt 2024 * | 1.46B 1.99B | Net Debt 2025 * | 1.28B 1.74B | EV / Sales 2025 * | 8.79 x |
P/E ratio 2024 * |
-24.3
x | P/E ratio 2025 * |
140
x | Employees | 999 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 27.24% |
Latest transcript on Alvotech
1 day | -0.14% | ||
1 week | +6.08% | ||
Current month | -0.14% | ||
1 month | +27.02% | ||
3 months | -7.77% | ||
6 months | +62.70% | ||
Current year | +26.13% |
Managers | Title | Age | Since |
---|---|---|---|
Vilhelm Wessman
CEO | Chief Executive Officer | 54 | 18-11-01 |
Joel Morales
DFI | Director of Finance/CFO | 46 | 20-01-31 |
Giedrius Zunda
CTO | Chief Tech/Sci/R&D Officer | - | 22-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Linda McGoldrick
BRD | Director/Board Member | 68 | 22-06-15 |
Helga Zharov
LAW | General Counsel | 57 | 20-04-30 |
Vilhelm Wessman
CEO | Chief Executive Officer | 54 | 18-11-01 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-02 | 14.51 | +0.21% | 231,629 |
24-05-01 | 14.48 | -0.14% | 118,095 |
24-04-30 | 14.5 | +1.97% | 224,692 |
24-04-29 | 14.22 | +0.49% | 39,632 |
24-04-26 | 14.15 | +3.66% | 248,476 |
End-of-day quote Nasdaq, May 30, 2024
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+26.13% | 4.06B | |
+26.28% | 48.09B | |
+48.09% | 40.62B | |
-3.99% | 40.43B | |
-6.20% | 28.36B | |
+6.36% | 24.89B | |
-21.47% | 19.01B | |
+27.58% | 12.09B | |
-2.02% | 11.88B | |
-2.75% | 11.8B |
- Stock Market
- Equities
- ALVO Stock